Advanced Search Results For "COVID-19 treatment"
Your filters
Safety profile and clinical results of Remdesivir in Hemodialysis patients infected with SARS-CoV-2. A single-center Spanish cohort study.
Publication Type: Editorial & Opinion
Source(s): Journal of nephrology [J Nephrol] 2023 Jan; Vol. 36 (1), pp. 171-172. Date of Electronic Publication: 2022 Jun 18.
Donor selection for adoptive cell therapy with CD45RA - memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release.
Publication Type: Academic Journal
Source(s): Cytotherapy [Cytotherapy] 2023 Mar; Vol. 25 (3), pp. 330-340. Date of Electronic Publication: 2022 Dec 12.
Abstract: Background Aims: We have previously demonstrated the safety and feasibility of adoptive cell therapy with CD45RA - memory T cells containing severe acute respiratory syndrome coronavirus 2-specific T cells for patients with coronavirus disease 2019 fro...
Non-anticoagulant heparin derivatives for COVID-19 treatment.
Publication Type: Academic Journal
Source(s): International journal of biological macromolecules [Int J Biol Macromol] 2023 Jan 31; Vol. 226, pp. 974-981. Date of Electronic Publication: 2022 Dec 14.
Abstract: The ongoing pandemic of COVID-19, caused by the infection of SARS-CoV-2, has generated significant harm to the world economy and taken numerous lives. This syndrome is characterized by an acute inflammatory response, mainly in the lungs and kidneys. Ac...
Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
Publication Type: Academic Journal
Source(s): Journal of medical virology [J Med Virol] 2022 Nov; Vol. 94 (11), pp. 5582-5588. Date of Electronic Publication: 2022 Aug 02.
Abstract: Since the start of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID-19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N-hydroxycytidin...
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study.
Publication Type: Academic Journal
Source(s): Current medical research and opinion [Curr Med Res Opin] 2022 Dec; Vol. 38 (12), pp. 2029-2033. Date of Electronic Publication: 2022 Oct 13.
Abstract: Introduction: Since the start of the SARS-CoV-2 pandemic, several treatment options have been proposed (e.g. steroids, heparin, antivirals and monoclonal antibodies). Remdesivir was the first antiviral approved for the treatment of COVID-19, even thoug...
Alamandine: A promising treatment for fibrosis.
Publication Type: Academic Journal
Source(s): Peptides [Peptides] 2022 Nov; Vol. 157, pp. 170848. Date of Electronic Publication: 2022 Aug 02.
Abstract: Angiotensin (Ang) II, the main active member of the renin angiotensin system (RAS), is essential for the maintenance of cardiovascular homeostasis. However, hyperactivation of the RAS causes fibrotic diseases. Ang II has pro-inflammatory actions, and m...
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies.
Publication Type: Academic Journal
Source(s): Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2021 Jul; Vol. 19 (7), pp. 877-888. Date of Electronic Publication: 2020 Dec 29.
Abstract: Introduction: To date, the transmission of Coronavirus Disease-2019 (COVID-19) is still uncontrollable with the fact that the numbers of confirmed and death cases are still increasing. Up to 1st October 2020, 33,842,281 confirmed cases and 1,010,634 co...
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Publication Type: Academic Journal
Source(s): Molecular and cellular biochemistry [Mol Cell Biochem] 2022 Mar; Vol. 477 (3), pp. 711-726. Date of Electronic Publication: 2022 Jan 11.
Abstract: The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first ...
Molnupiravir: A new candidate for COVID-19 treatment.
Publication Type: Academic Journal
Source(s): Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Feb; Vol. 10 (1), pp. e00909.
Abstract: The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate ...
Role of Imaging and AI in the Evaluation of COVID-19 Infection: A Comprehensive Survey.
Publication Type: Academic Journal
Source(s): Frontiers in bioscience (Landmark edition) [Front Biosci (Landmark Ed)] 2022 Sep 30; Vol. 27 (9), pp. 276.
Abstract: Coronavirus disease 2019 (COVID-19) is a respiratory illness that started and rapidly became the pandemic of the century, as the number of people infected with it globally exceeded 253.4 million. Since the beginning of the pandemic of COVID-19, over tw...